June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Dependency of BCVA and ranibizumab treatment frequency of DME patients in a real-life setting (OCEAN study)
Author Affiliations & Notes
  • Focke Ziemssen
    Center of Ophthalmology, University Tuebingen, Tuebingen, Germany
  • Jessica Voegeler
    Novartis, Nuernberg, Germany
  • Steffen Schmitz-Valckenberg
    University Eye Hospital, Bonn, Germany
  • Georg Spital
    Department of Ophthalmology, St. Franziskus-Hospital, Muenster, Germany
  • Sandra Liakopoulos
    Cologne Image Reading Center, Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships   Focke Ziemssen, Alcon (R), Alimera (C), Allergan (C), Allergan (R), Bayer Healthcare (C), Bayer Healthcare (R), Biogen (R), Boehringer Ingelheim (C), Novartis (C), Novartis (R); Jessica Voegeler, Novartis (E); Steffen Schmitz-Valckenberg, Alcon/Novartis (C), Alcon/Novartis (F), Allergan (F), Allergan (R), Carl Zeiss Meditec (F), Formycon (F), Genentech/Roche (F), Genentech/Roche (C), Genentech/Roche (R), Heidelberg Engineering (F), Heidelberg Engineering (R), Optos (F); Georg Spital, Allergan (R), Bayer Healthcare (R), Heidelberg Engineering (R), Novartis (F), Novartis (R), Pfizer (R); Sandra Liakopoulos, Allergan (R), Bayer (R), Heidelberg Engineering (R), Novartis (R), Novartis (C)
  • Footnotes
    Support  Novartis
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1904. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Focke Ziemssen, Jessica Voegeler, Steffen Schmitz-Valckenberg, Georg Spital, Sandra Liakopoulos; Dependency of BCVA and ranibizumab treatment frequency of DME patients in a real-life setting (OCEAN study). Invest. Ophthalmol. Vis. Sci. 2017;58(8):1904.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To date there are little prospective data investigating DME patients in a real-life setting. Randomized controlled trials have already proven the favourable effect of vascular endothelial growth factor (VEGF) inhibition with ranibizumab in several indications including diabetic macula edema (DME). In order to gain knowledge of the relevant hurdles and barriers and the impact of optical coherence tomography (OCT) diagnostic on the treatment with ranibizumab the OCEAN included a subgroup of DME patients.

Methods : In the non-interventional, prospective OCEAN study 5.779 patients are monitored in a prospective manner over 24 month (NCT02194803). The 12-month interim analysis of 1217 patients diagnosed with DME (57.44% female/42.07% male) with an average age of 67.6 years. The following data were recorded and analyzed: number of visits, best corrected visual acuity (BCVA), number of injections and the use of diagnostic tools and adverse events.

Results : With an average of 4.4.injections, initial baseline BCVA of 60.6 ETDRS letters increased to 64.9 ± 19.5 letters after 12 months (a gain of 4.3 letters). Patients receiving 7 or more injections gained 6.1 letters. 40.67% patients gained ≥ 5 letters, while 27.77% patients gained ≥ 10 letters and 18.32% ≥ 15 letters. A time-to-response analysis showed that patients receiving at least 7 injections reached the 15-letter threshold earlier.
Patients had an average of 9.6 BCVA assessments and 3.9 OCT examinations during the first year. A higher amount of patients achieved ≥ 10 letters, when more OCTs were taken for disease monitoring: 23.53% for one or less OCT, 35.74% when 4 to 6 OCT examinations were done. The safety profile of ranibizumab was consistent with previously reported DME studies with no new safety findings.
An update of the final 24-months data will be presented.

Conclusions : Favorable effects of ranibizumab on visual acuity of DME patients are detected after 12 months in an interim analysis of the real-life OCEAN trial. This improvement was shown to be dependent on the number of injections. Furthermore there might be a relationship between the number of OCT-examinations and BCVA improvement. Our data shows that relevant BCVA gain is more likely to be achieved with sufficient treatment and follow-up in real-life setting.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.